Panobinostat for the treatment of multiple myeloma: the evidence to date

References

• GozzettiACandiVPapiniGBocchiaMTherapeutic advancements in multiple myelomaFront Oncol2014424125237651
   PubMedGoogle Scholar
• SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin20156552925559415
   PubMed Web of Science ®Google Scholar
• MateosMVOcioEMSan MiguelJFNovel generation of agents with proven clinical activity in multiple myelomaSemin Oncol201340561863324135407
   PubMed Web of Science ®Google Scholar
• BrennerHGondosAPulteDRecent major improvement in long-term survival in younger patients with multiple myelomaBlood20081112521252617901246
   PubMed Web of Science ®Google Scholar
• OrlowskiRZNovel agents for multiple myeloma to overcome resistance in Phase III clinical trialsSemin Oncol201340563465124135408
   PubMed Web of Science ®Google Scholar
• KumarSKTherneauTMGertzMAClinical course of patients with relapsed multiple myelomaMayo Clin Proc20047986787415244382
   PubMed Web of Science ®Google Scholar
• HideshimaTAndersonKCMolecular mechanisms of novel therapeutic approaches for multiple myelomaNat Rev Cancer200221292793712459731
   PubMed Web of Science ®Google Scholar
• KhanOLa ThangueNBHDAC inhibitors in cancer biology: emerging mechanisms and clinical applicationsImmunol Cell Biol2012901859422124371
   PubMed Web of Science ®Google Scholar
• MaesKMenuEVan ValckenborghEVan RietIVanderkerkenKDe BruyneEEpigenetic modulating agents as a new therapeutic approach in multiple myelomaCancers20135243046124216985
   PubMedGoogle Scholar
• RoperoSEstellerMThe role of histone deacetylases (HDACs) in human cancerMol Oncol200711192519383284
   PubMed Web of Science ®Google Scholar
• FragaMFBallestarEVillar-GareaALoss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancerNat Genet20053739140015765097
   PubMed Web of Science ®Google Scholar
• AronsonLIDaviesFEDanger: protein overload. Targeting protein degradation to treat myelomaHaematologica20129781119113022580998
   PubMed Web of Science ®Google Scholar
• KaleAJMooreBSMolecular mechanisms of acquired proteasome inhibitor resistanceJ Med Chem20125523103171032722978849
   PubMed Web of Science ®Google Scholar
• YanJInterplay between HDAC6 and its interacting partners: essential roles in the aggresome-autophagy pathway and neurodegenerative diseasesDNA Cell Biol201433956758024932665
   PubMed Web of Science ®Google Scholar
• LavelleDChenYHHankewychMDeSimoneJHistone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expressionAm J Hematol200168317017811754398
   PubMed Web of Science ®Google Scholar
• CatleyLWeisbergETaiYTNVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myelomaBlood200310272615262212816865
   PubMed Web of Science ®Google Scholar
• MitsiadesNMitsiadesCSRichardsonPGMolecular sequelae of histone deacetylase inhibition in human malignant B cellsBlood2003101104055406212531799
   PubMed Web of Science ®Google Scholar
• MitsiadesCSMitsiadesNSMcMullanCJTranscriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implicationsProc Natl Acad Sci U S A2004101254054514695887
   PubMed Web of Science ®Google Scholar
• Garnock-JonesKPPanobinostat: first global approvalDrugs20157569570425837990
   PubMed Web of Science ®Google Scholar
• AtadjaPDevelopment of the pan-DAC inhibitor panobinostat (LBH589): successes and challengesCancer Lett2009280223324119344997
   PubMed Web of Science ®Google Scholar
• Andreu-VieyraCVBerensonJRThe potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myelomaTher Adv Hematol20145619721025469210
   PubMedGoogle Scholar
• HideshimaTRichardsonPGAndersonKCMechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myelomaMol Cancer Ther201110112034204222072815
   PubMed Web of Science ®Google Scholar
• OcioEMVilanovaDAtadjaPIn vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myelomaHaematologica201095579480319951978
   PubMed Web of Science ®Google Scholar
• DeAngeloDJSpencerABhallaKNPhase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignanciesLeukemia20132781628163623385375
   PubMed Web of Science ®Google Scholar
• WolfJLSiegelDGoldschmidtHPhase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myelomaLeuk Lymphoma20125391820182322288662
   PubMed Web of Science ®Google Scholar
• San-MiguelJFRichardsonPGGuntherAPhase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myelomaJ Clin Oncol201331293696370324019544
   PubMed Web of Science ®Google Scholar
• RichardsonPGSchlossmanRLAlsinaMPANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myelomaBlood2013122142331233723950178
   PubMed Web of Science ®Google Scholar
• RichardsonPGSchlossmanRLAlsinaMTime to event analyses in PANORAMA 2: a phase 2 study of panobinostat, bortezomib, and dexamethasone in patients with relapsed and bortezomib-refractory multiple myelomaBlood2013122211970
   Web of Science ®Google Scholar
• San-MiguelJFHungriaVTYoonSPanobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trialLancet Oncol201415111195120625242045
   PubMed Web of Science ®Google Scholar
• Arastu-KapurSAnderlJLKrausMNonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse eventsClin Cancer Res20111792734274321364033
   PubMed Web of Science ®Google Scholar
• BerdejaJGHartLLMaceJRPhase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myelomaHaematologica2015100567067625710456
   PubMed Web of Science ®Google Scholar
• BerensonJRHilgerJDYellinOA phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myelomaAnn Hematol2014931899824135804
   PubMed Web of Science ®Google Scholar
• OffidaniMPolloniCCavalloFPhase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myelomaLeuk Lymphoma20125391722172722335534
   PubMed Web of Science ®Google Scholar
• MishimaYSantoLEdaHRicolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell deathBr J Haematol2015169342343425709080
   PubMed Web of Science ®Google Scholar
• Farydak^® (panobinostat capsules) [prescribing information]East Hanover, NJNovartis Pharmaceuticals Corporation2015 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdfAccessed April 15, 2015
   Google Scholar
• SharmaSBeckJMitaMA phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumorsInvest New Drugs201331497498523377661
   PubMed Web of Science ®Google Scholar
• SlingerlandMHessDCliveSA phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic functionCancer Chemother Pharmacol20147451089109825253045
   PubMed Web of Science ®Google Scholar